New drug regulations in France: what are the impacts on market access? Part 2–impacts on market access and impacts for the pharmaceutical industry

Journal of Market Access and Health Policy

Volumn 1, Issue 1, 2013, Pages

  Rémuzat, Cécile ^a   Toumi, Mondher ^b   Falissard, Bruno ^c  

^a CREATIV CEUTICAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Universite Paris Sud   (France)

Author keywords

comparative evidence; drugs; France; law; market access; medico economic assessment; pricing; reimbursement

Indexed keywords

EID: 84936877531     PISSN: None     EISSN: 20016689     Source Type: Journal    
DOI: 10.3402/jmahp.v1i0.20892     Document Type: Article

References (17)

1. Legifrance. Law no. 2011–2012 of the 29th of December 2011 related to the reinforcement of the health safety of drugs and health products. 2011. Available from: http://www.legifrance.gouv.fr/affichTexte.do;jsessionid=?cidTexte=JORFTEXT000025053440&dateTexte=&oldAction=rechJO&categorieLien=id [cited 6 January 2012].
2. Legifrance. Law no. 2011–1906 of the 21st of December 2011 related to the social security funding law for 2012. 2011. Available from: http://www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000025005833&dateTexte= [cited 6 January 2012].
3. French Senate. Steps of the law related to the reinforcement of the health safety of drug and health products. 2011. Available from: http://www.senat.fr/dossier-legislatif/pjl11-005.html [cited 6 January 2012].
4. JaroslawskiS, ToumiM. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res. 2011; 11: 259.
5. Contractual framework dated 5 December 2012 between the CEPS and the pharmaceutical companies.2012. Available from: http://www.sante.gouv.fr/IMG/pdf/accord_cadre_du_051212.pdf [cited 11 March 2013].
6. HAS. Guide méthodologique–choix méthodologiques pour l’évaluation économique à la HAS. 2011. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf [cited 18 April 2012].
7. French Parliament. LFSS 2012–scheme of the legislative procedure. 2011. Available from: http://www.assemblee-nationale.fr/13/dossiers/plfss_2012.asp [cited 12 December 2011].
8. HAS. Rapport d'activité 2011. 2012. Available from: http://www.has-sante.fr/portail/jcms/c_1267546/rapport-annuel-d-activite-2011 [cited 24 September 2012].
9. Legifrance. Bill for the reinforcement of the health safety of drug and health products, impact study. 2011. Available from: http://www.legifrance.gouv.fr/Droit-francais/Etudes-d-impact/Lois-en-preparation [cited 12 December 2011].
10. APM International. AFSSAPS refuses the recommendations of one of its working group due to links of interests. 2011. Available from: http://www.specialitesmedicales.org/wp-content/uploads/Afssaps-rejet-recommandation-experts.pdf [cited 6 February 2012].
11. General Inspection of Social Affairs (IGAS). Evaluation du dispositif de financement des médicaments en sus des prestations d'hospitalisation dans les établissements de santé. 2012. Available from: http://www.igas.gouv.fr/IMG/pdf/RM2012-044P_Financement_Medic_en_sus_.pdf [cited 20 October 2012].
12. ToumiM, MuellerT. From decision point to decision window: readiness for a change of paradigm. Germany: Berlin. Workshop at ISPOR 15th Annual European Congress, 3–7 November 2012.
13. HAS. CT–opinion Cymbalta. 2007. Available from: http://www.has-sante.fr/portail/upload/docs/application/pdf/ct-2319_cymbalta_.pdf [cited 25 February 2013].
14. AMELI. Drug and prices database. 2013. Available from: http://www.codage.ext.cnamts.fr/codif/bdm_it//fiche/index_fic_medisoc.php?p_code_cip=3400936586451&p_site=AMELI [cited 25 February 2013].
15. Pichetti S, Sermet C. Analysis of the impact of drug delisting in France between 2002 and 2011. Questions d’économie de la santé. 2011; 167. Available from: http://www.irdes.fr/EspaceAnglais/Publications/IrdesPublications/QES167.pdf [cited 12 December 2012].
16. General Inspection of Social Affairs (IGAS). Evaluation du dispositif de financement des médicaments en sus des prestations d'hospitalisation dans les établissements de santé. 2012. Available from: http://www.igas.gouv.fr/IMG/pdf/RM2012-044P_Financement_Medic_en_sus_.pdf [cited 20 October 2012].
17. General Inspection of Social Affairs (IGAS). Pour la maîtrise de l'ONDAM 2013–2017. 2012. Available from: http://www.economie.gouv.fr/files/rapport_ondam_igas-igf.pdf [cited 20 October 2012].